Metastasis is the chief cause of mortality from cancer, but the mechanisms leading to metastasis are poorly understood. We used a proteomics approach to screen for metastasis-associated proteins and found that collapsin response mediator protein-4 (CRMP4) expression was inversely associated with the lymph node metastasis of prostate cancer (PCa). Subsequent in vitro and in vivo studies revealed that overexpression of CRMP4 not only suppressed the invasion ability of PCa cells, but also strongly inhibited tumor metastasis in an animal model. Furthermore, methylation of a CpG island within the promoter region of the CRMP4 gene is responsible for downregulation of CRMP4 expression. Thus, in this study, we show new function of CRMP4 as a metastasissuppressor in PCa. The findings provide new mechanistic insights into metastasis and therapeutic potential for this most common male cancer.
Introduction
Prostate cancer (PCa) is the most common solid organ malignancy affecting men and the second leading cause of cancer death in the United States (Jemal et al., 2008) . Metastatic cancers, once established, are the main cause of mortality associated with cancer. Metastasis is a complex and multistage process involving local invasion, intravasation, successful transit through the bloodstream, extravasation, and eventual proliferation and survival within a favorable target organ (Loberg et al., 2005) . Recently, technological advances permit the genomic characterization of tumors, enhancing our understanding of cancer initiation and metastasis. Cancers are a heterogeneous mass of neoplastic cells with various properties, including different metastatic activity (Lapointe et al., 2004; Shaffer and Pandolfi, 2006; Tomlins et al., 2007) . During carcinogenesis, some tumor cells probably acquire new phenotypes by increased expression of metastasis-promoting genes or decreased expression of metastasis-suppressor genes (Klein, 2008) . However, the identification of individuals at increased risk of metastasis, who may then be selected for aggressive systemic therapy, remains a considerable challenge.
PCa often migrates through the lymphatic route, depositing tumor cells into pelvic lymph nodes (Miyake et al., 2007) . Among the adverse pathological features, the presence of pelvic lymph node metastasis is the strongest predictor of poor outcome (Burton et al., 2008) . Proteomics-based expression profiling has been commonly used to compare and contrast heterogeneous groups of human tumors (Hanash, 2003) . In this study, we used two-dimensional (2D) fluorescence difference gel electrophoresis (DIGE) technique coupled with matrixassisted laser desorption/ionization time-of-flight/timeof-flight mass spectrometry analysis to identify differentially expressed proteins in pelvic lymph node metastatic PCa (LNM PCa) compared with localized PCa. We selected the differentially expressed protein, collapsin response mediator protein-4 (CRMP4), validated its preferentially suppressed expression in metastatic PCa, and showed its contribution to the metastasis-suppressing process in a series of functional studies.
Results

Identification of differentially expressed CRMP4 in metastatic PCa
By comparing protein proles from fresh-frozen LNM PCa and localized PCa tissues using the 2D DIGE technique with matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry analysis, CRMP4 was identified for the first time to be downregulated by 1.86-fold in the LNM PCa. The expression of CRMP4 was significantly decreased in LNM PCa compared with localized PCa (Po0.001; Figure 1 ). We further determined whether its expression was associated with the metastasis of PCa. Western blot and real-time reverse transcriptase PCR (RT-PCR) were used to verify that the proteomics data were an accurate representation of the CRMP4 gene expression patterns in PCa. As predicted, the expression of CRMP4 protein was significantly decreased in LNM PCa tissues compared with localized PCa tissues (P ¼ 0.007; Figure 2a ). CRMP4 gene expression was also significantly decreased in LNM PCa tissues by real-time PCR (Po0.001; Figure 2b ). CRMP4 protein expression was also assessed in archival formalin fixed PCa and benign prostate hyperplasia (BPH) specimens by immunohistochemistry (IHC). Notably, CRMP4 expression was detected mainly in cytoplasm of epithelial cells and its expression was intensive in all BPH specimens. In constrast, CRMP4 expression was significantly downregulated in LNM PCa tissues compared with localized PCa tissues (Po0.001; Figure 2c and Supplemental Figure 5A ).
To examine the specificity of CRMP4 expression, we analyzed the expression patterns of all five members of the CRMP gene family (CRMP1, CRMP2, CRMP3, CRMP4 and CRMP5) in BPH and PCa tissues by real-time RT-PCR. Of all CRMP family members, the CRMP4 gene was determined to be the only one differentially expressed in PCa tissue (all P-values >0.05; Figure 2e ). We also examined CRMP4 expression in other endoblast-derived cancers including lung, gastric and intestine cancers by western blot and confirmed that the decreased expression pattern of CRMP4 is specific in LNM PCa (Figure 2d ).
Overexpression of CRMP4 and inhibition of metastasis in vitro and in vivo To examine the role of expression of CRMP4 in metastasis, a CRMP4 expression vector was stably introduced into two PCa cell lines (PC3 and LNCaP) and clones that stably expressed CRMP4 were isolated. Interestingly, transfected PC3 and LNCaP cells with high CRMP4 expression became rounded and seldom have filopodia protruding from the cell edge following actin filaments staining with FITC-conjugated phalloidin, but mock-transfected cells maintained a flat, spindle-and fibroblast-like morphology and showed numerous filopodia (Figure 3a, Supplemental Figure 1 ). PCa cells transiently transfected with the plasmid pEGFP-CRMP4, carrying the fusion gene for enhanced green fluorescent protein (EGFP)-tagged CRMP4, were examined directly and found that CRMP4 diffusely distributed in the cytoplasm (Figure 3a) . Transfected clones expressed higher levels of CRMP4 than the mock-transfected clones (Figure 3b ). The same fluorescence intensity in the two stable cells (PC3-pEGFP-C1 and PC3-pEFGP-CRMP4) was observed (Supplemental Figure 6 ) and a modified 3-(4,5)-dimethyl-thiahiazo CRMP4, a novel metastasis suppressor gene in PCa X Gao et al (-z-y1)-3,5-diphenytetrazoliumromide assay showed that in vitro proliferation was essentially unchanged with altered CRMP4 expression. We then used an in vitroreconstituted basement membrane invasion assay to investigate whether CRMP4 expression affected the invasive ability of PC3 and LNCaP cells. After a 48-h incubation, we noted a statistically significant reduction in the invasive activity of CRMP4-expressing clones compared with control clones (Po0.001, Po0.001, respectively; Figures 3c and d) .
We then addressed the potential functional role of CRMP4 as a metastasis-suppressor gene by metastatic assays in vivo by assessing the effect of restoring CRMP4 expression to PC3 cells. PC3 cells expressing either empty vector (pEGFP-c1) or CRMP4 expression vector (pEGFP-CRMP4) with GFP reporter were injected into mouse prostate (Figure 3e) . At specified time, the organs, including lung, liver, kidney, pancreas and prostate, were dissected from each mouse and GFP activities, representative of metastasis, were recorded. Although the primary tumor weights as well as associated-GFP activities in prostate were comparable both in control and in CRMP4-expressing tumor cells, there were significant decreases in liver, lung and kidney metastases in CRMP4-expressing PC3 cells (Figures 3f  and g ). These results indicate that expression of CRMP4 in PCa cells significantly suppresses the in vivo incidence of metastases.
Identification of 5
0 CpG island methylation of the CRMP4 gene promoter To investigate the mechanism for the downregulation of CRMP4 expression in metastatic PCa, we further analyzed the structure of the CRMP4 promoter region. (a) Western blot analyses of CRMP4 expression in BPH and PCa. There was a signicant difference in CRMP4 expression level among groups (P ¼ 0.007, One-way ANOVA). CRMP4 expression was significantly downregulated in LNM PCa tissues (P ¼ 0.031, compared with the BPH group; P ¼ 0.007, compared with the localized PCa group, Newman-Keuls test). GAPDH was used as the internal loading control. (b) Real-time RT-PCR analysis of CRMP4 expression. There was a signicant difference in CRMP4 expression level among groups (Po0.001, One-way ANOVA). The expression of CRMP4 gene was significantly decreased in LNM PCa tissues (Po0.001, compared with the BPH group; Po0.001, compared with the localized PCa group, Newman-Keuls test). (c) Immunohistochemical analysis of CRMP4 in BPH tissue, localized and LNM PCa. The arrows indicate the positive staining in prostate glandular epithelium. The LNM PCa group had significantly lower expression of CRMP4 than that in the localized PCa group. (d) Western blot analyses of specific decreased expression of CRMP4 in metastatic PCa. There was no decreased expression of CRMP4 in all other endoblasts-derived metastatic tumor tissues including lung, gastric, intestine cancer. GAPDH was used as the internal loading control. (e) The expression of all other CRMP family members (CRMP1, CRMP2, CRMP3 and CRMP5) in BPH, localized PCa and LNM PCa tissues by real-time RT-PCR. There were no significant differences in all other CRMP family members (CRMP1, CRMP2, CRMP3 and CRMP5) among these three groups (all P-values >0.05, one-way ANOVA).
CRMP4, a novel metastasis suppressor gene in PCa X Gao et al First, the sequences of CRMP4 promoter region were amplified by PCR and sequenced in two metastatic PCa tissues and three PCa cell lines (PC3, PC3M and LNCaP). No mutations were found in the sequences of CRMP4 promoter region from À940 to the transcriptional start site (Supplemental Figure 2B) .
However, we identified two CpG islands in the 5 0 -flanking sequences with the program MethPrimer (http://www.urogene.org/methprimer/) (Supplemental Figure 2A ). We used bisulfite-sequencing PCR to find all methylation alleles in metastatic PCa tissues and PCa cell lines compared with localized PCa and BPH tissues ( Figure 4A and Supplemental Figures 3 and 4) . The results revealed the methylation status of 43 CpG dinucleotides in the CpG island 1 ( Figure 4A ) and 27 CpG dinucleotides in the CpG island 2 
-test).
Results were the means of three separate measurements obtained from three separate experiments. (e) PC3 cells expressing GFP reporter with either empty vector (pEGFP-c1) or CRMP4 expression vector (pEGFP-CRMP4) were injected into mouse prostate, and GFP activity was recorded for each mouse (n ¼ 9 mice per group). (f) GFP activity in lung, liver, kidney and pancreas, representative of metastasis, was recorded for each mouse. Organ images from different mice were shown. The color bar represents GFP intensity. (g) GFP activities in the organs from either each control mouse or each CRMP4-expressing mouse were quantified, and the ratios of GFP activities in the metastatic organ relative to primary prostate tumor were shown. There were significant decreases in liver, lung and kidney metastases in the CRMP4-expressing PC3 cells compared with mock-transfected PC3 cells.
CRMP4, a novel metastasis suppressor gene in PCa X Gao et al (Supplemental Figure 3) . Our data showed that the CpG sites in À848, À841, À690, À680, À678, À674, À671, À665, À660 and À658 of CpG island 1 were highly or moderately methylated in cell lines (PC3, PC3M and DU145) and metastatic PCa (primary lesion and metastatic lymph node). In contrast, these CpG sites in localized PCa, BPH and normal prostate were mostly unmethylated except a few sporadic 5-methylcytosine in some of the clones. Thus, we used methylation specific PCR (MSP) to detect the presence of specific methylation alleles of CpG island 1 in five of seven metastatic PCa and three PCa cell lines ( Figure 4B ). The treatment with demethylating agent 5-aza-2-deoxycytidine in PC3 cells was effective for reexpression of CRMP4 ( Figure 4C ). Furthermore, western blot was used to validate the correlation of the promoter methylation with decreased CRMP4 expression in metastatic PCa ( Figure 4D ) and in PCa cell lines (Figure 3b ).
Association of CRMP4 expression with postoperative biochemical relapse, clinical metastasis and VEGF expression in PCa tissue
We used IHC to examine CRMP4 expression in archival formalin fixed tissue from 65 cases of PCa (localized PCa, n ¼ 38; LNM PCa, n ¼ 27) and 20 cases of BPH. Staining intensity was quantified using Image-Pro Plus software. As mentioned above, the expression level of CRMP4 in LNM PCa specimens (7.21 ± 1.26 integrated optical density units) was statistically significantly lower than in localized PCa tissue (17.12±1.37 integrated optical density units, Po0.001) and in BPH tissue (27.46 ± 2.84 integrated optical density units, Po0.001; Supplemental Figure 5A ). Four cases with localized PCa (Patients 1-4 in Supplemental Figure 5B ), who had relatively lower CRMP4 expression level at diagnosis, had a rapid biochemical relapse and clinical metastasis. Furthermore, there was a trend of decreased expression level of CRMP4 in these cases when they progressed from localized lesions to metastatic ones (Supplemental Figures 5B and C) . In contrast, two cases (Patient M3 and M7 in Figure 5b ) in LNM PCa groups had relatively higher expression level of CRMP4 and their CpG sites were mostly unmethylated, validated by MSP ( Figure 4B ). The case (Patient M3) had no biochemical relapse (undetectable serum prostate specific antigen) and clinical metastatic findings until 2-year follow-up. We also used IHC to examine simultaneously CRMP4 and vascular endothelial growth factor (VEGF) expression in archival formalin fixed tissue from 32 cases of prostate tissues (BPH, n ¼ 10; localized PCa, n ¼ 10; LNM PCa, n ¼ 12). These results showed that the CRMP4 expression was inversely associated with VEGF expression in PCa tissues (Figures 5a and b ; r ¼ À0.612, Po0.001).
Discussion
To become metastatic, tumor cells must coordinate the increased expression of metastasis-promoting genes and/or the decreased expression of metastasis-suppressing genes (Steeg, 2003) . The advent of DIGE-based proteomics technology, in which the expression of thousands of proteins can be assessed simultaneously, has greatly facilitated the dissection of this process (Hanash, 2003; Go¨rg et al., 2004) . Lymphatic invasion is one of the major routes for cancer cell dissemination and lymph node status provides important information for both diagnosis and treatment of human cancer (Kishimoto et al., 2006; de Boer et al., 2009 ). Here we describe the use of the 2D DIGE proteomics analysis to identify a set of proteins whose expression is associated with pelvic lymph node metastasis in PCa. We experimentally demonstrate in vivo, for the first time, the functional metastasis-suppressing role of the gene, CRMP4.
CRMP4 is a member of the CRMP family of cytosolic phosphoproteins, which may mediate semaphorin/collapsin-induced growth cone collapse and are involved in axonal guidance and neuronal differentiation (Goshima et al., 1995; Gaetano et al., 1997; Fukada et al., 2000) . During the last few years, five members of the CRMP gene family (CRMP1, CRMP2, CRMP3, CRMP4 and CRMP5), encoding closely related 60-66 kDa proteins, have been cloned and they have 50-70% sequence homology with one another (Wang and Strittmatter, 1997; Arimura et al., 2000) . A previous study has reported that CRMP1 is an invasion suppressor and correlates with clinical outcomes in non-small-cell lung cancer. They further characterized that CRMP1 was a novel invasion-suppression gene (Shih et al., 2001 (Shih et al., , 2003 . Here we found that expression of both CRMP4 mRNA and protein was inversely associated with the lymph node metastasis of PCa and that overexpression of CRMP4 in PCa cell lines reduced its in vitro invasive activity. Furthermore, we demonstrated experimentally that forced expression of CRMP4 in PCa cell lines induces a decreased metastatic state in a mouse model of PCa metastasis. The expression of CRMP1, CRMP2, CRMP3 and CRMP5 mRNAs in the PCa specimens was investigated using real-time RT-PCR analyses, but no association between these CRMP family members and metastasis in PCa could be established. These findings support the notion that CRMP4 has new function as a metastasis suppressor in PCa.
Although efforts over the past two decades have identified metastasis suppressors ranging from kinases, such as MAP kinase kinase 4, to GTP-binding proteins, such as Rho-GDI2, only a limited number of metastasissuppressor genes have been identified to date, and mechanistic details for most of these genes are largely unknown (Rinker-Schaeffer et al., 2006). We showed that the level of CRMP4 protein was statistically significantly higher in localized PCa compared with metastatic PCa, suggesting that the level of CRMP4 protein decreases during clinical disease when cells acquire the ability to grow at a metastatic site. CRMP4, on reexpression in metastatic PCa cell lines, reduced metastasis without a significant effect on tumorigenicity. As such, it will be important to integrate CRMP4 function into the context of other known metastasis suppressors, including both novel (NM23, BRMS1, CRMP4, a novel metastasis suppressor gene in PCa X Gao et al KiSS1 and KAI1) and known (MKK4 and RKIP) metastasis suppressors (Steeg, 2006) .
The CRMP4 protein encodes a 62-kDa protein with no signal sequence, transmembrane domain or classical protein interaction domains. However, CRMP4 contains a number of consensus phosphorylation sites that may serve as substrates for signaling molecules, such as Cdk, protein kinase C and proline-directed kinases (Gaetano et al., 1997) . CRMP4 are intracellular phosphoproteins involved in rib-like actin bundles in CRMP4, a novel metastasis suppressor gene in PCa X Gao et al lamellipodia and functionally regulates the actin cytoskeleton in motile cells (Rosslenbroich et al., 2005) , which may be relevant for metastasis suppressing. However, in the case of a newly characterized metastasis suppressor such as CRMP4, determining its biochemical mechanism of action still remains daunting. Cancer has long been thought to progress through accumulation of genetic mutations. However, it has become increasingly clear that epigenetic mechanisms have a central role in tumorigenesis (Feinberg et al., 2006; Ting et al., 2006) . In eukaryotes, DNA methylation of gene promoters is associated with transcriptional repression (Zilberman, 2007) . The CRMP4 gene, which locates on human chromosome 5q32, contains 15 exons, including an exon defined by an anaplastic oligodendroglioma-expressed sequence tag, and spans at least 61.7 kb (Matsuo et al., 2000) . We found no mutations in the sequences of CRMP4 promoter core region in either metastatic PCa or PCa cell lines. Indeed, the promoters of several tumor-suppressor genes, such as p16, p15 and E-cadherin, are highly methylated with a rare gene mutation in human oral squamous-cell carcinoma (Uzawa et al., 2002) . Here we detected methylation of the CRMP4 gene promoter region in metastatic PCa and in PCa cell lines and validated that the promoter methylation was correlated with the level of CRMP4 expression in metastatic PCa and in PCa cell lines. Therefore, these observations suggest that CRMP4 promoter methylation, but not mutational inactivation is likely the main mechanism of CRMP4 downregulation.
Abnormal methylation in the neighborhood of the start codon has been shown to suppress gene expression in tumor cells by either interfering with RNA polymerase II initiation or transcription factor binding (Tate and Bird, 1993) . Several regions of the promoter of the CRMP4 gene have been shown to be potentially relevant for the regulation of its expression (Matsuo et al., 2000) . The sequence contained between À439 and À163 bp from the start codon of the CRMP4 gene is rich in potential binding sites for several transcription factors, such as Oct-1, ets-1, c-Myc, MyoD/myogenin, Sp1 and Ap-1 (Matsuo et al., 2000) . Upregulation of these transcription factors in cancer cells would potentially correlate with an increase in the levels of CRMP4 and an enhanced cancer metastasis-suppressive action. However, abnormal methylation of this promoter region prevents CRMP4 expression with concomitant loss of its metastasis-repressor function (Figure 5c ).
VEGFs, among major pro-angiogenic and pro-metastatic molecules, are indirect promoters of tumor growth in vivo by inducing angiogenesis and lymphangiogenesis, which is crucial for supporting expansion of tumor mass and metastases (Chi et al., 2009) . Some of the abovementioned transcription factors (Sp1, Ap-1, ets-1) are known to be upregulated in tumor cells and can switch on the expression of VEGF (Schewe et al., 2005; Seth and Watson, 2005; Ozanne et al., 2007) . Sema3A, also known as collapsin-1, can inhibit the migration or motility of endothelial cells by depolymerization of F-actin and retraction of lamellipodia (Miao et al., 1999) . Neuropilin-1 and plexin A1 are required for Sema3A to initiate the signal transduction cascade. VEGF and Sema3A are competitive inhibitors that have overlapping neuropilin-1 binding sites (Miao et al., 1999) . A recent study has reported that VEGF and Sema3A, as antagonistic autocrine neuropilin-1 ligands, have a key role in PCa progression (Yacoub et al., 2009) . CRMPs can mediate the signal of Sema3A-neuropilins and the expression of CRMPs are positively associated with that of Sema3A (Shih et al., 2001; Deo et al., 2004) . Thus, we presume that abnormal methylation of the promoter region in CRMP4 prevents CRMP4 expression, which might indirectly increase the VEGF expression, thus contributes to PCa metastasis. However, further studies are needed to confirm the underlying mechanisms.
In conclusion, we have identified, to our knowledge, for the first time, that CRMP4 has new function as a metastasis suppressor in PCa. Our studies directly shown that overexpression of CRMP4 not only suppressed the ability of PCa cells to invade matrigel in vitro, but also strongly inhibited tumor metastasis in an animal model. Methylation of a CpG island within the promoter region of the CRMP4 is responsible for downregulation of CRMP4 expression in metastatic PCa. Realization of the mechanism regulating the expression of CRMP4 will lead to the development of new strategies for the treatment of PCa, possibly by increasing the amount of CRMP4 to halt cancer metastasis. CRMP4, a novel metastasis suppressor gene in PCa X Gao et al
Materials and methods
Human PCa specimens and cell line Primary PCa specimens and pelvic lymph nodes were freshly collected from patients during surgery in the Third Affiliated Hospital of Sun Yat-sen University. All procedures were approved by the research committee of the hospital and all samples were obtained with the consent of the research subjects. For 2D DIGE proteome analysis, 10 cases of localized PCa, 7 cases of LNM PCa and 10 cases of BPH CRMP4, a novel metastasis suppressor gene in PCa X Gao et al were collected. With regard to confirmatory studies, real-time RT-PCR was performed on 16 localized PCa tissues, 16 LNM PCa tissues and 16 BPH tissues for determining the expression of CRMP1, CRMP2, CRMP3, CRMP4 and CRMP5.
Western blot was performed on nine localized PCa tissues, nine LNM PCa tissues and nine BPH tissues for determining the expression of CRMP4. Paraffin-embedded specimens from 38 cases of localized PCa, 27 cases of LNM PCa and 20 cases of BPH were used to validate the expression of CRMP4 using IHC. Human prostate cancer cell lines (PC3, PC3M, DU145 and LNCaP) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Proteomic analysis
A modified manual microdissection method was used to obtain pure tumor tissue (Paris et al., 2004) . Tissue (B0.1 g) was homogenized in lysis buffer (7 M urea, 2 M thiourea, 30 mM Tris, 4% (w/v) CHAPS, 40 mM dithiothreitol, 0.6 mM phenylmethylsulfonyl fluoride). The supernatant was collected, purified with a 2D cleanup kit (GE Healthcare BioSciences, Little Chalfont, UK), quantified with the 2D Quant kit (GE Healthcare), and labeled with CyDye DIGE Fluors following the Ettan DIGE user manual as described previously (Fu et al., 2007) . A total of 2800-3000 protein spots were analyzed across all samples. The ratios of protein abundance that increased or decreased X1.5-fold (Po0.01; Jackson et al., 2006) were considered significantly changed. The corresponding differential protein spots with statistical significance and high abundance in both preparative gels were selected for spot picking. The selected protein spots in the preparative gels were automatically picked up and handled in the Ettan Spot Handling Workstation (GE Healthcare). The criteria of successfully identified protein as follows: ion score confidence interval (CI%) for PMF and MS/MS data X95%, peptide count (hit) X4 and at least two peptides of distinct sequence were identified in MS/MS analysis.
Real-time PCR
Total RNA was extracted after homogenization of tissue samples using TRIzol (Invitrogen, Carlsbad, CA, USA), followed by DNase digestion (RNase-free DNase set; Qiagen, Valencia, CA, USA) and on-column clean up with the RNeasy MinElute kit (Qiagen). Total RNA (2 mg) was reverse transcribed with the Superscript II RNase H-reverse transcriptase kit (Invitrogen) for complementary DNA (cDNA) synthesis using random hexamer primers. Expression level and genomic copy number were evaluated by real-time PCR on an ABI PRISM 7000 Sequence Detector Thermocycler (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's protocol. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was applied as the input references. Sequences of PCR primers of CRMP1-5 are available on request. All quantitative PCR reactions were performed in triplicate and repeated at least twice. The DCt for gene-specific mRNA expression was calculated relative to the Ct (threshold cycle) of GAPDH. The DDCt was calculated by normalizing to the average DCt of the 16 BPH tissue samples.
Western blot
In total, 60 mg of each protein sample was subjected to western blot analysis using anti-CRMP4 (1:7500; Chemicon Inc., Temecula, CA, USA). GAPDH was used as an internal control in all blotting membranes (anti-GAPDH, 1:1000; Cell Signaling Technology, Inc., Beverly, MA, USA). Immunoreactive proteins were then visualized using the ECL western blotting system (Pierce Biotechnology, Rockford, IL, USA). Images were scanned by the ImageMaster II scanner (GE Healthcare) and analyzed using ImageQuant TL v2003.03 (GE Healthcare). Background binding was subtracted out, and the band signals were expressed as relative protein amounts compared with GAPDH.
IHC
Immunohistochemical staining was respectively performed with anti-CRMP4 (1:1500) and anti-VEGF (1:100, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) using the DAKO En-Vision System (Dako Diagnostics, Zug, Switzerland) according to the manufacturer's instructions. Positive immunostaining was visualized and recorded by an experienced pathologist (Z-L S) in a blinded manner. Staining intensity was quantified over three randomly selected, high-powered fields per section using Image Pro-Plus software, version 4.0 (Media Cybernetics, Bethesda, MD, USA) and is expressed as integrated optical density units of staining intensity per field of vision (Cathcart et al., 2008; Yang et al., 2008) .
Molecular cloning and plasmid constructs cDNA encoding the entire human CRMP4 coding region (GenBank accession number NM_001387) was amplified by PCR using above cDNA synthesis from BPH tissues. Primer sequences were as follows: 5 0 -GAATTCGGTACCATGTCC TACCAAGGCAAGAAGA-3 0 (sense), 5 0 -CTCGAGCCCGGG GTTAACTCAGAGATGTGATATTAG-3 0 (antisense; 1737 bps). The CRMP4 cDNA fragment was cloned into a pMD19-T simple vector and sequenced with an autosequencer (model ABI 377; PE Applied Biosystems, Foster City, CA, USA). Sequence analysis showed a 100% match to the published sequence for CRMP4 cDNA. pcDNA3.1-CRMP4 was created by inserting CRMP4 cDNA between the Kpn I and Xhol I sites of a pcDNA3.1 mammalian expression vector (Promega Corp., Madison, WI, USA). At the same time, the CRMP4 cDNA was inserted in frame between the Kpn I and Smal I sites of an EGFP expression vector, pEGFP-C1 (Clontech, Palo Alto, CA, USA), yielding pEGFP-CRMP4, which CRMP4, a novel metastasis suppressor gene in PCa X Gao et al produced the EGFP-tagged CRMP4 protein. These constructs were isolated from plasmid clones and sequenced on both strands with an autosequencer (model ABI377; PE Applied Biosystems).
Transfection and selection pcDNA3.1-CRMP4 and pEGFP-CRMP4 plasmids were transfected into 70% confluent PC3 cells with DMRIE-C reagent (Invitrogen Inc.) according to the manufacturer's instructions. Other PC3 cells were transfected with the pcDNA3.1( þ ) plasmids or pEGFP-c1 vector containing no insert (mock transfected) as a control. Gentamicin (G418; Life Technologies, Inc., Rockville, MD, USA) was added to 500 ng/ml for the selection of stable transfectants. Selection medium was changed every 3 days for a 3-week period. Clones of resistant cells were isolated and allowed to proliferate for further characterization. For transient transfections, 70% confluent cultures of LNCap and PC3 cells were transfected with the pEGFP-CRMP4 plasmid as above. Living cells were examined directly and photographed under inverted fluorescence microscope, after 48 h.
Matrigel invasion assay
The invasive activities of transfected clones PC3-pcDNA3.1-CRMP4 and LNCap-pcDNA3.1-CRMP4 were examined by using a membrane invasion culture system, in which a polycarbonate membrane with 8-mm pores (Nucleopore Corp., Pleasanton, CA, USA) coated with Matrigel at 5 mg/ml was placed between the upper and lower well plates of a membrane invasion culture system chamber. The mock transfected cells were used as a control (Cai et al., 2008) . Similar data were obtained from at least three independent experiments.
In vivo metastasis assay All procedures using animals were approved by and were in accordance with the guidelines of the Animal Care and Use Committee of Third Affiliated Hospital of Sun Yat-sen University. PC3 cells expressing either empty vector (pEGFP-C1) or CRMP4 expression vector (pEGFP-CRMP4) with GFP reporter were sorted and recollected with fluoresence-activated cell sorting (Becton Dickinson, Franklin Lakes, NJ, USA), and injected into the prostate of male BALB/c nude mice (n ¼ 9 mice per group, 6 weeks of age, 2 Â 10 5 cells per mouse). At 45 days after injection, mice were killed and the images of GFP intensity were taken (Singh et al., 2007) . The prostate, lung, liver, kidney and pancreas were dissected from each mouse and GFP activities, representative of metastasis, in different organs including lung, liver, kidney and pancreas were recorded with in vivo Imaging System IVIS 200 (Xenogen, Alameda, CA, USA).
Detection of methylation of the CRMP4 promoter Demethylation drug treatment. PC3 cells were first cultured in 100-mm plates until 40% conuent and subsequently treated with 0.5, 5 and 12.5 mM 5-aza-2-deoxycytidine (Sigma, St Louis, MO, USA) for 5 days, respectively. The cells were then collected for protein extraction by western blot analysis.
DNA isolation DNA was extracted from frozen tissue samples using universal genomic DNA extraction kit (TaKaRa Bio Inc., Otsu, Shiga, Japan) according to the manufacturer's instructions.
Sequence analysis of promoter region
The promoter region (Matsuo et al., 2000) , containing À940 to the transcriptional start site, was amplified by PCR. Genomic DNA was extracted from cancer samples, from metastatic PCa patients M3 and M6, and from cell lines PC3, PC3M and LNCaP. The retrieved DNA was used directly as templates in PCR reactions consisting of 0.02 mM each of the forward (5 0 -ATGGGGAGCAATAGCAGTTCTACTC-3 0 ) and reverse (5 0 -AGCGGACAGGGAGCGAGCGAGG-3 0 ) primers using LA Taq polymerase (TaKaRa). The purified products were then cloned into the TA cloning vector pMD18-T Simple Vector (TaKaRa), and 20 positive clones were randomly selected for sequence analysis.
Sodium bisulfite modification of DNA Bisulfite modification of genomic DNA was performed as described previously (Clark et al., 1994; Herman et al., 1996) , using MethylDetector Bisulfite Modification Kit (Active Motif) and stored at À80 1C until use.
Bisulfite-sequencing PCR
In 5 0 -flanking sequences of CRMP4, two CpG islands were found using the program MethPrimer. CpG island 1 contained partial sequences of exon anaplastic oligodendroglioma, and CpG island 2 contained partial sequences of exon anaplastic oligodendroglioma and exon 1. The nested PCR was conducted to determine the methylation patterns of the CpG islands of CRMP4 promoter using the outer and inner primers (Supplemental Table 1 ). The purified PCR products were subcloned into pMD19-T Simple Vector (TaKaRa), and 10 positive clones of each product were randomly selected for sequence analysis.
MSP
MSP was used to detect the presence of methylated alleles for specific genes. According to the bisulfate-sequencing PCR results, the MSP primer pairs for CRMP4 were designed complying with the standard rules (Li and Dahiya, 2002; Brandes et al., 2007) to detect the methylation status of CpG island 1. The first step and second step PCR were amplified, as the same as bisulfate-sequencing PCR. The third step PCR were performed with a primer set specific to the methylated or unmethylated sequence (M or U set) described in Supplemental Table 2 . PCR products were loaded onto 3% agarose gels, stained with ethidium bromide and visualized under ultraviolet light.
Statistical analysis
To compare the relative abundance of individual protein spot features among multiple groups, we performed a one-way ANOVA followed by Newman-Keuls test. For comparisons between two groups, Student's t test was used. One-way ANOVA followed by Newman-Keuls test was also used to evaluate the differences in western blot, real-time RT-PCR and IHC results. Data were analyzed using SPSS 16.0 software package (SPSS, Chicago, IL, USA) and a two-tailed P-value of o0.05 was considered statistically significant.
Abbreviations
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